Cumberland Pharmaceuticals, Inc. (CPIX)
| Market Cap | 49.55M |
| Revenue (ttm) | 40.86M |
| Net Income (ttm) | -3.42M |
| Shares Out | 15.13M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $3.30 |
| Previous Close | $3.22 |
| Change ($) | 0.08 |
| Change (%) | 2.48% |
| Day's Open | 3.20 |
| Day's Range | 3.12 - 3.58 |
| Day's Volume | 503,450 |
| 52-Week Range | 2.90 - 5.00 |
NASHVILLE, Tenn., Nov. 17, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announced today the launch of RediTrex® (methotrexate) ...
Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q3 2020 Results - Earnings Call Transcript
Cumberland (CPIX) delivered earnings and revenue surprises of 128.57% and 7.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Cumberland (NASDAQ:CPIX) were flat after the company reported Q3 results. Quarterly Results Earnings per share increased 100.00% over the past year to $0.02, which beat the estimate ...
NASHVILLE, Tenn., Nov. 10, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 f...
Cumberland (NASDAQ: CPIX) unveils its next round of earnings this Tuesday, November 10. Get prepared with Benzinga's ultimate preview for Cumberland's Q3 earnings.
NASHVILLE, Tenn., Nov. 3, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2020 financial results and Company update after...
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ATLANTA, Sept. 28, 2020 /PRNewswire/ -- Women's apparel and fashion accessories retailer, Charming Charlie, today announced that it will open its first physical store at the Cumberland Mall in...
SAN JOSE, Calif.--(BUSINESS WIRE)---- $CALX #Calix--Cumberland Connect is deploying FTTH with Calix and has completed an end-to-end network integration 83 percent faster than industry standards
NASHVILLE, Tenn., Aug. 18, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.
Cumberland (CPIX) delivered earnings and revenue surprises of 166.67% and 3.54%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Cumberland (NASDAQ:CPIX) rose 2.07% in after-market trading after the company reported Q2 results.
NASHVILLE, Tenn., Aug. 11, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.
Cumberland (NASDAQ: CPIX) releases its next round of earnings this Tuesday, August 11.
NASHVILLE, Tenn., Aug. 4, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.
NASHVILLE, Tenn., July 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.
Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NASHVILLE, Tenn., May 26, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announces a new publication in Drugs - Real World Outcom...
Cumberland (CPIX) delivered earnings and revenue surprises of -50.00% and -11.93%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
NASHVILLE, Tenn., May 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today prov...
Here are four top-ranked liquid gems that investors can add to portfolio for remarkable returns.
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.
In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.
Cumberland Pharmaceuticals Inc (CPIX) CEO A. J. Kazimi on Q4 2019 Results - Earnings Call Transcript
Cumberland Pharmaceuticals Inc (CPIX) CEO A. J. Kazimi on Q4 2019 Results - Earnings Call Transcript
Cumberland (CPIX) delivered earnings and revenue surprises of 800.00% and 20.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cumberland Pharmaceuticals' (CPIX) CEO A. J. Kazimi on Q3 2019 Results - Earnings Call Transcript
Cumberland (CPIX) delivered earnings and revenue surprises of -90.91% and -18.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Cumberland Pharmaceuticals (CPIX) closed at $5.56 in the latest trading session, marking a -0.18% move from the prior day.
Cumberland Pharmaceuticals' (CPIX) third-quarter results are expected to reflect solid sales growth.
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cumberland Pharmaceuticals (CPIX) closed at $5.34 in the latest trading session, marking a +0.75% move from the prior day.
Cumberland Pharmaceuticals (CPIX) closed at $5.30 in the latest trading session, marking a -1.6% move from the prior day.
Cumberland Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Cumberland (CPIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q2 2019 Results - Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q2 2019 Earnings Conference Call August 14, 2019 4:30 PM ET
Cumberland (CPIX) delivered earnings and revenue surprises of 42.86% and -8.01%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, Cumberland Pharmaceuticals (CPIX) closed at $6.35, marking a +0.79% move from the previous day.
Is (CPIX) Outperforming Other Medical Stocks This Year?
Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Cumberland (CPIX) possesses solid growth attributes, which could help it handily outperform the market.
Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q1 2019 Results - Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2019 Results Earnings Conference Call May 14, 2019 4:30 PM ET
Cumberland (CPIX) delivered earnings and revenue surprises of 200.00% and 11.24%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.
About CPIX
Cumberland Pharmaceuticals, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care and gastroenterology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duo... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Aug 11, 2009 |
| CEO A. J. Kazimi | Employees 94 |
| Stock Exchange NASDAQ | Ticker Symbol CPIX |
Financial Performance
In 2019, CPIX's revenue was $47.53 million, an increase of 16.67% compared to the previous year's $40.74 million. Losses were -$3.54 million, -49.19% less than in 2018.
Analyst Forecasts
According to one analyst, the rating for CPIX stock is "Strong Buy" and the 12-month stock price forecast is 8.50.